.Pharmacolibrary.Drugs.S_SensoryOrgans.S01C_AntiinflammatoryAgentsAndAntiinfectivesInCombina.S01CB01_Dexamethasone.Dexamethasone

Information

name:Dexamethasone
ATC code:S01CB01
route:intravenous
n-compartments2

Dexamethasone is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressant properties. It is commonly used in the treatment of a variety of conditions, including allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, and respiratory disorders. It is approved and widely used today in both oral and parenteral formulations.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult subjects after intravenous administration.

References

  1. Li, L, et al., & Endeman, H (2023). Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: Does inflammation play a role?. Journal of critical care 78 154395–None. DOI:10.1016/j.jcrc.2023.154395 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37542750

  2. Guthrie, S (1991). The impact of dexamethasone pharmacokinetics on the DST: a review. Psychopharmacology bulletin 27(4) 565–576. PUBMED:https://pubmed.ncbi.nlm.nih.gov/1813902

  3. Nijstad, AL, et al., & Zwaan, CM (2022). Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 30(12) 9991–9999. DOI:10.1007/s00520-022-07423-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36287279

Revisions


Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos